Showing 3601-3610 of 5773 results for "".
- Aldeyra Therapeutics Submits NDA to the FDA for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-submits-nda-to-the-fda-for-reproxalap-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2481263/Aldeyra Therapeutics announced the submission of a new drug application (NDA) to the FDA for topical ocular reproxalap, an investigational new drug candidate for the treatment of signs and symptoms of dry eye disease. The NDA submission is supported by safety and efficacy
- Kala Pharmaceuticals Submits of Investigational NDA for KPI-012 for the Treatment of Persistent Corneal Epithelial Defecthttps://modernod.com/news/kala-pharmaceuticals-submits-of-investigational-nda-for-kpi-012-for-the-treatment-of-persistent-corneal-epithelial-defect/2481262/Kala Pharmaceuticals announced the submission of an investigational new drug application (NDA) to the FDA for KPI-012 for the treatment of persistent corneal epithelial defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a phase 2b cli
- BTIG to Host Ophthalmology Day on November 29, 2022https://modernod.com/news/btig-to-host-ophthalmology-day-on-november-29-2022/2481261/Global financial services firm BTIG announced that "Ophthalmology Day at BTIG" will take place on November 29, 2022. The virtual, 1-day event will include thematic panel discussions, one-on-one meetings and company presentations. The event will be hosted by:
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Graybug and CalciMedica Enter Into Definitive Merger Agreementhttps://modernod.com/news/graybug-and-calcimedica-enter-into-definitive-merger-agreement/2481257/Graybug Vision and CalciMedica announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica’s lead product candidate Auxora, a proprietary, intr
- Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 for Retinal Diseaseshttps://modernod.com/news/kinarus-receives-uspto-notice-of-allowance-for-lead-therapeutic-candidate-kin001-for-retinal-diseases/2481256/Kinarus Therapeutics announced the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases" covering its therapeutic candidate KIN001 in age-relat
- Sightpath Medical Acquires Accusite Surgicalhttps://modernod.com/news/sightpath-medical-acquires-accusite-surgical/2481253/Sightpath Medical announced that it has acquired Accusite Surgical, a cataract surgery equipment outsourcing company. Terms of the deal were not disclosed. Founded in 1991, Sightpath Medical delivers custom access to ophthalmic equipment, instruments, and services. Through its patented
- FDA Grants Breakthrough Therapy Designation for Iveric Bio's Avacincaptad Pegol for Geographic Atrophyhttps://modernod.com/news/fda-grants-breakthrough-therapy-designation-for-iveric-bios-avacincaptad-pegol-for-geographic-atrophy/2481251/Iveric bio announced that the FDA has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). To date, A
- Staar Surgical Opens EVO Experience Center in United Stateshttps://modernod.com/news/staar-surgical-opens-evo-experience-center-in-united-states/2481249/Staar Surgical announced the opening of the first company-operated EVO Experience Center. The center is located at Staar's corporate headquarters in Lake Forest, California. “We are very excited to open the first company-operated EVO Experience Center for ophthalmic
- Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosahttps://modernod.com/news/kiora-pharmaceuticals-doses-first-patient-in-abacus-phase-1b-study-evaluating-kio-301-for-retinitis-pigmentosa/2481248/Kiora Pharmaceuticals announced the dosing of the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with retinitis pigmentosa (RP). "We are thrilled the first patient has been treated and I'm very enc